LT2753313T - Farmacinės kompozicijos, apimančios aromatazės inhibitorių - Google Patents

Farmacinės kompozicijos, apimančios aromatazės inhibitorių

Info

Publication number
LT2753313T
LT2753313T LTEP12758966.1T LT12758966T LT2753313T LT 2753313 T LT2753313 T LT 2753313T LT 12758966 T LT12758966 T LT 12758966T LT 2753313 T LT2753313 T LT 2753313T
Authority
LT
Lithuania
Prior art keywords
pharmaceutical compositions
aromatase inhibitor
aromatase
inhibitor
pharmaceutical
Prior art date
Application number
LTEP12758966.1T
Other languages
English (en)
Inventor
Ann Taylor
Lloyd B. Klickstein
Jeewan Thakur
Original Assignee
Mereo Biopharma 2 Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46846026&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT2753313(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mereo Biopharma 2 Limited filed Critical Mereo Biopharma 2 Limited
Publication of LT2753313T publication Critical patent/LT2753313T/lt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833Encapsulating processes; Filling of capsules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/485Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06Anabolic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26Androgens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
LTEP12758966.1T 2011-09-08 2012-09-06 Farmacinės kompozicijos, apimančios aromatazės inhibitorių LT2753313T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161532459P 2011-09-08 2011-09-08
US201261638588P 2012-04-26 2012-04-26
PCT/US2012/053846 WO2013036563A1 (en) 2011-09-08 2012-09-06 Pharmaceutical compositions comprising an aromatase inhibitor

Publications (1)

Publication Number Publication Date
LT2753313T true LT2753313T (lt) 2017-02-10

Family

ID=46846026

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP12758966.1T LT2753313T (lt) 2011-09-08 2012-09-06 Farmacinės kompozicijos, apimančios aromatazės inhibitorių
LTEP12758965.3T LT2753312T (lt) 2011-09-08 2012-09-06 Aromatazės inhibitoriaus panaudojimas hipogonadizmo ir susijusių ligų gydymui

Family Applications After (1)

Application Number Title Priority Date Filing Date
LTEP12758965.3T LT2753312T (lt) 2011-09-08 2012-09-06 Aromatazės inhibitoriaus panaudojimas hipogonadizmo ir susijusių ligų gydymui

Country Status (30)

Country Link
US (4) US9370505B2 (lt)
EP (2) EP2753313B1 (lt)
JP (2) JP6280501B2 (lt)
KR (3) KR101872561B1 (lt)
CN (2) CN103781476B (lt)
AR (1) AR087790A1 (lt)
AU (2) AU2012304694B2 (lt)
BR (2) BR112014005434B1 (lt)
CA (2) CA2845929C (lt)
CL (1) CL2014000552A1 (lt)
CY (2) CY1118461T1 (lt)
DK (2) DK2753312T3 (lt)
ES (2) ES2613667T3 (lt)
HR (2) HRP20170003T1 (lt)
HU (2) HUE031478T2 (lt)
IL (1) IL231234A (lt)
IN (1) IN2014DN01619A (lt)
LT (2) LT2753313T (lt)
MX (2) MX360315B (lt)
PE (1) PE20141584A1 (lt)
PL (2) PL2753313T3 (lt)
PT (2) PT2753313T (lt)
RU (2) RU2628808C2 (lt)
SG (2) SG10201607503WA (lt)
SI (2) SI2753312T1 (lt)
TN (1) TN2014000059A1 (lt)
TW (1) TW201316987A (lt)
UY (1) UY34315A (lt)
WO (2) WO2013036563A1 (lt)
ZA (1) ZA201401040B (lt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2753312T3 (da) * 2011-09-08 2017-02-13 Mereo Biopharma 2 Ltd Anvendelse af en aromatase-inhibitor i behandlingen af hypogonadisme og relaterede sygdomme
US10324099B2 (en) * 2014-03-26 2019-06-18 The Regents Of The University Of California Ultrasensitive androgen receptor bioassay
US10143680B2 (en) * 2014-07-07 2018-12-04 Novartis Ag Pharmaceutical dosage forms
GB201614179D0 (en) * 2016-08-19 2016-10-05 Mereo Biopharma 2 Ltd Dosage regimen for the treatment of endometriosis
EP3592338A1 (en) * 2017-03-08 2020-01-15 ARIAD Pharmaceuticals, Inc. Pharmaceutical formulations comprising 5-chloro-n4
USD894149S1 (en) * 2018-08-16 2020-08-25 Alibaba Group Holding Limited Information terminal for payment
USD894148S1 (en) * 2018-08-16 2020-08-25 Alibaba Group Holding Limited Information terminal for payment
JP7121999B2 (ja) * 2019-09-26 2022-08-19 学校法人九州文化学園 男性性腺機能低下症治療剤

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4749713A (en) 1986-03-07 1988-06-07 Ciba-Geigy Corporation Alpha-heterocycle substituted tolunitriles
TW210334B (lt) * 1990-12-12 1993-08-01 Ciba Geigy Ag
DE4435368A1 (de) * 1994-09-22 1996-03-28 Schering Ag Verwendung von Aromatasehemmern zur Herstellung eines Arzneimittels zur Behandlung eines relativen Androgenmangels beim Mann
US5972921A (en) * 1997-12-12 1999-10-26 Hormos Medical Oy Ltd. Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men
AU2001271162A1 (en) * 2000-07-05 2002-01-14 Astrazeneca Ab Pharmaceutical combination of an anti-androgen and letrozole for providing an anit-androgenic effect and aromatase inhibition
EP1381431B1 (en) 2001-04-17 2007-06-06 Ares Trading S.A. Aromatase inhibition to enhance implantation rate
US7101573B2 (en) 2001-09-28 2006-09-05 Mcneil-Pcc, Inc. Simethicone solid oral dosage form
EP1492515A1 (en) 2002-04-03 2005-01-05 Jencap Research Ltd. Pharmaceutical composition comprising an aromatase inhibitor and an estrogen suitable for hormone replacement therapy for a male
CA2605796A1 (en) * 2005-04-25 2006-11-02 Pfizer Products Inc. Pharmaceutical compositions and methods comprising a combination of a selective estrogen receptor modulator and an aromatase inhibitor
CN101868243A (zh) 2007-11-21 2010-10-20 客乐谐制药株式会社 芳香酶抑制剂
DK2753312T3 (da) * 2011-09-08 2017-02-13 Mereo Biopharma 2 Ltd Anvendelse af en aromatase-inhibitor i behandlingen af hypogonadisme og relaterede sygdomme

Also Published As

Publication number Publication date
JP2014528932A (ja) 2014-10-30
ES2613666T3 (es) 2017-05-25
CA2846884C (en) 2019-04-09
RU2014113575A (ru) 2015-10-20
AU2012304693B2 (en) 2016-03-31
EP2753312A1 (en) 2014-07-16
US10064844B2 (en) 2018-09-04
DK2753313T3 (en) 2017-02-13
SG2014012132A (en) 2014-06-27
CL2014000552A1 (es) 2014-09-12
IL231234A0 (en) 2014-04-30
BR112014005434A2 (pt) 2017-04-04
HUE031435T2 (en) 2017-07-28
CN103781476A (zh) 2014-05-07
US20160346257A1 (en) 2016-12-01
ZA201401040B (en) 2015-12-23
MX343902B (es) 2016-11-28
LT2753312T (lt) 2017-01-25
PL2753313T3 (pl) 2017-07-31
CN103781476B (zh) 2016-12-07
JP6280501B2 (ja) 2018-02-14
JP6051467B2 (ja) 2016-12-27
SG10201607503WA (en) 2016-10-28
AU2012304693A1 (en) 2014-03-13
IN2014DN01619A (lt) 2015-05-15
BR112014005434B1 (pt) 2021-01-05
US9295668B2 (en) 2016-03-29
CY1118461T1 (el) 2017-07-12
US20140309267A1 (en) 2014-10-16
CA2845929C (en) 2018-06-19
BR112014004879B1 (pt) 2020-01-28
KR20180030254A (ko) 2018-03-21
HRP20170003T1 (hr) 2017-03-10
EP2753312B1 (en) 2016-12-14
BR112014004879A2 (pt) 2017-03-14
KR20140071358A (ko) 2014-06-11
CA2845929A1 (en) 2013-03-14
EP2753313B1 (en) 2016-12-14
TW201316987A (zh) 2013-05-01
KR20140058619A (ko) 2014-05-14
EP2753313A1 (en) 2014-07-16
ES2613667T3 (es) 2017-05-25
SI2753313T1 (sl) 2017-04-26
NZ621476A (en) 2016-02-26
JP2014526465A (ja) 2014-10-06
MX360315B (es) 2018-10-29
US9750724B2 (en) 2017-09-05
IL231234A (en) 2016-12-29
TN2014000059A1 (en) 2015-07-01
UY34315A (es) 2013-04-30
SI2753312T1 (sl) 2017-10-30
RU2617510C2 (ru) 2017-04-25
CN103796644B (zh) 2017-05-03
US20160243084A1 (en) 2016-08-25
MX2014002773A (es) 2014-06-05
HUE031478T2 (hu) 2017-07-28
RU2014113334A (ru) 2015-10-20
PE20141584A1 (es) 2014-11-13
CY1118499T1 (el) 2017-07-12
WO2013036562A1 (en) 2013-03-14
AR087790A1 (es) 2014-04-16
PT2753313T (pt) 2017-02-02
CN103796644A (zh) 2014-05-14
PL2753312T3 (pl) 2017-06-30
US20140213622A1 (en) 2014-07-31
PT2753312T (pt) 2017-02-03
WO2013036563A1 (en) 2013-03-14
HRP20170002T1 (hr) 2017-02-24
MX2014002780A (es) 2014-06-05
CA2846884A1 (en) 2013-03-14
DK2753312T3 (da) 2017-02-13
AU2012304694B2 (en) 2016-04-07
KR101872561B1 (ko) 2018-06-28
RU2628808C2 (ru) 2017-08-22
AU2012304694A1 (en) 2014-03-20
US9370505B2 (en) 2016-06-21

Similar Documents

Publication Publication Date Title
HK1201212A1 (en) Hemostatic compositions
HK1201186A1 (en) Solid compositions comprising an hcv inhibitor hcv
HK1200371A1 (en) Neprilysin inhibitors
IL231961A0 (en) Bleeding agents
GB201113662D0 (en) Pharmaceutical compositions
IL232147A0 (en) Bleeding agents
PL2791160T3 (pl) Kompozycje zmodyfikowanego mrna
EP2683693A4 (en) ROR-GAMMA-T INHIBITORS
ZA201305826B (en) Substituted amminobutyric derivatives as neprilysin inhibitors
ZA201308208B (en) Pharmaceutical compositions
HK1199824A1 (en) Pharmaceutical compositions
PL3513803T3 (pl) Kompozycje hemostatyczne
LT2753313T (lt) Farmacinės kompozicijos, apimančios aromatazės inhibitorių
IL226554A (en) Medicinal preparations containing alisporiovir
GB201118181D0 (en) Pharmaceutical compositions
EP2714715A4 (en) PHARMACEUTICAL COMPOSITIONS
ZA201309537B (en) Pharmaceutical composition comprising fexofedine
PT2701729T (pt) Composições hemostáticas
GB201120474D0 (en) Inhibitors